Related Experiment Video
Updated: May 19, 2026

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level
Published on: January 19, 2024
Anemia correction using Roxadustat among MHD patients: 50mg versus 100mg dosing schedules
Alam K S1, Masud Iqbal M1, Rokhsana Alam Ripa1
1Department of Nephrology, National Institute of Kidney Disease & Urology, Dhaka, Bangladesh.
Abstract:
Anemia is a common complication in maintenance hemodialysis (MHD) patients. Hence, roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, was evaluated at two dosing schedules (50 mg versus 100 mg) in a randomized, open-label study of 65 patients. Both doses significantly increased hemoglobin and reduced red cell transfusion requirements over 12 weeks. The 100 mg dose produced a quicker and more pronounced response. Headaches were frequent but manageable and blood pressure remained stable. Roxadustat was well tolerated, supporting its role as a viable treatment option for anemia in dialysis patients.
Related Concept Videos
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Dosage Regimen: Individualization
Drug Dosing: Geriatric Patients
Drug Dosing: Obese Patients
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
